Monoclonal antibodies for treating osteoporosis.

about

Osteoporosis Therapy With Denosumab in Organ Transplant Recipients.Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts.

P2860

Q55068120-9F4CE190-A155-4D19-95FC-E2C621338B3A Q55082811-E5E7F9D8-6F10-4A19-ADB7-A3470DFA95AB

P2860

Monoclonal antibodies for treating osteoporosis.

Item

http://www.wikidata.org/entity/Q47638169

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Monoclonal antibodies for treating osteoporosis.

@en

Monoclonal antibodies for treating osteoporosis.

@nl

type

Item

label

Monoclonal antibodies for treating osteoporosis.

@en

Monoclonal antibodies for treating osteoporosis.

@nl

prefLabel

Monoclonal antibodies for treating osteoporosis.

@en

Monoclonal antibodies for treating osteoporosis.

@nl

P1476

Monoclonal antibodies for treating osteoporosis.

@en

P2093

Gabriele D'amato

http://www.w3.org/2001/XMLSchema#string

Graziana Colaianni

http://www.w3.org/2001/XMLSchema#string

Maria Felicia Faienza

http://www.w3.org/2001/XMLSchema#string

Maria Grano

http://www.w3.org/2001/XMLSchema#string

Mariangela Chiarito

http://www.w3.org/2001/XMLSchema#string

Silvia Colucci

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

Pathogenesis of osteoporosis: concepts, conflicts, and prospects

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab

Bone mineral density in sclerosteosis; affected individuals and gene carriers

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

P304

149-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14712598.2018.1401607

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giacomina Brunetti

P577

2017-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29113523

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

Monoclonal antibodies for treating osteoporosis.

about

P2860

P2860

Monoclonal antibodies for treating osteoporosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921